This activity is supported by an educational grant from: Alexion Pharmaceuticals

James F. Howard, Jr., MD - (Bio)

A Rationale for the Use of Targeted Therapies of Myasthenia Gravis
This course will aid in recognizing the disease and treatment burdens of patients with myasthenia gravis, the role of complement inhibition in the treatment of myasthenia gravis and the potential role of FcRn inhibition in the treatment of myasthenia gravis.
1 AMA PRA Category 1 Credit ™
Norman Latov, MD, PhD - (Bio)

Pathogenic Mechanisms in Immune Mediated Neuropathies; Role of Complement
This course will review the clinical presentation, evaluation, diagnosis, and treatment of the immune mediated neuropathies, with an emphasis on the known disease mechanisms and role of the complement.

1 AMA PRA Category 1 Credit ™
Marinos Dalakas, MD - (Bio)

Role of Complement in Autoimmune Neurological Diseases and Emerging Complement – Targeted Therapies.
This course will review the role of complement in health and inflammatory or autoimmune neurological diseases and identify the factors that activate complement, what happens if complement is activated and highlight the new agents that inhibit complement activation.
1 AMA PRA Category 1 Credit ™
Marinos Dalakas, MD - (Bio)

Immunopathology of Inflammatory Myopathies and the Role of Complement
This course will review the immunopathology of the five distinct subtypes of inflammatory myopathies: DM, Overlap Myositis, Necrotizing Autoimmune Myotosis, Polymyositis, IBM.
1 AMA PRA Category 1 Credit ™
REGISTER
LOGIN